145 related articles for article (PubMed ID: 28181841)
1. Surface density of polyarginine influence the size, zeta potential, cellular uptake and tissue distribution of the nanostructured lipid carrier.
Sun M; Zhu Z; Wang H; Han C; Liu D; Tian L; Yang X; Pan W
Drug Deliv; 2017 Nov; 24(1):519-526. PubMed ID: 28181841
[TBL] [Abstract][Full Text] [Related]
2. Polyarginine and PEG-AEYLR comodified nanostructured lipid carrier: 10mol% uncleavable PEG-AEYLR showed no shielding effect to polyarginine in vitro while maintaining good tumor targeting in vivo.
Sun M; Zhu Z; Wang H; Jin S; Yang X; Han C; Pan W
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):284-292. PubMed ID: 28355889
[TBL] [Abstract][Full Text] [Related]
3. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
Li F; Weng Y; Wang L; He H; Yang J; Tang X
Int J Pharm; 2010 Jun; 393(1-2):203-11. PubMed ID: 20385221
[TBL] [Abstract][Full Text] [Related]
5. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells.
Zhang YL; Zhang ZH; Jiang TY; Ayman-Waddad ; Jing-Li ; Lv HX; Zhou JP
Pharmazie; 2013 Jan; 68(1):47-53. PubMed ID: 23444780
[TBL] [Abstract][Full Text] [Related]
6. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
7. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
[No Abstract] [Full Text] [Related]
8. Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment.
Huang R; Li J; Kebebe D; Wu Y; Zhang B; Liu Z
Drug Deliv; 2018 Nov; 25(1):757-765. PubMed ID: 29528244
[TBL] [Abstract][Full Text] [Related]
9. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
10. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
11. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
Pinheiro M; Ribeiro R; Vieira A; Andrade F; Reis S
Drug Des Devel Ther; 2016; 10():2467-75. PubMed ID: 27536067
[TBL] [Abstract][Full Text] [Related]
12. A systematic
Sun M; Gao Y; Zhu Z; Wang H; Han C; Yang X; Pan W
Asian J Pharm Sci; 2017 Jan; 12(1):51-58. PubMed ID: 32104313
[TBL] [Abstract][Full Text] [Related]
13. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology.
Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S
Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
15. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
16. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
[TBL] [Abstract][Full Text] [Related]
17. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
18. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
19. Redox sensitive PEG controlled octaarginine and targeting peptide co-modified nanostructured lipid carriers for enhanced tumour penetrating and targeting in vitro and in vivo.
Wang H; Sun M; Li D; Yang X; Han C; Pan W
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):313-322. PubMed ID: 28362124
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.
Emami J; Rezazadeh M; Sadeghi H; Khadivar K
Pharm Dev Technol; 2017 May; 22(3):370-382. PubMed ID: 27689412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
